Desmopressin in nocturnal enuresis.

Terho P

The Journal of urology1 Apr 1991Cited by 38 (Europe PMC)

PMID2005708DOI10.1016/s0022-5347(17)38461-6PepBankPUB-02005708

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study11

11 results from studies that gave the peptide. 11 results from people.

01HumanRandomized controlled trialEfficacy outcome
In children with nocturnal enuresis, first-period dry nights averaged 4.3 per week with desmopressin and 2.1 with placebo.
In plain wordsIn children with bedwetting, first-period dry nights averaged 4.3 per week with desmopressin and 2.1 with placebo.
Peptide
Desmopressin
Outcome
IncreaseDry nights in first treatment periods versus placebo
Study
n = 52
Comparator
Placebo
Outcome group
Urinary Continence · Kidney and urinary
Studied dose
20 micrograms · intranasal · two periods of 3 weeksAs given in this study (human).
Measurements
Dry nights
4.3 nights/week
first desmopressin period
Dry nights
2.1 nights/week
first placebo period
Source sentences
Summary
The number of dry nights, measured as calculated averages per week, increased significantly (p less than 0.01) from 0.6 dry nights during pre-treatment to 4.3 and 4.6 dry nights per week during the 2 desmopressin treatment periods, respectively.
3 context sentences(design, population, supporting numbers)
Summary · context
The placebo responses were 2.1 and 2.4 dry nights per week, respectively.
Summary · context
The effect of intranasal desmopressin on primary nocturnal enuresis was investigated in a study divided into 2 parts in which the first part was a randomized, double-blind, placebo-controlled cross-over study of 52 Finnish school children 5 to 13 years old.
Summary · context
The patients were randomized to 4 periods of 3 weeks each: 2 periods on placebo and 2 periods on 20 micrograms. desmopressin spray.
Report a problemFND-0200570803
02HumanRandomized controlled trialEfficacy outcome
In children with nocturnal enuresis, second-period dry nights averaged 4.6 per week with desmopressin and 2.4 with placebo.
In plain wordsIn children with bedwetting, second-period dry nights averaged 4.6 per week with desmopressin and 2.4 with placebo.
Peptide
Desmopressin
Outcome
IncreaseDry nights in second treatment periods versus placebo
Study
n = 52
Comparator
Placebo
Outcome group
Urinary Continence · Kidney and urinary
Studied dose
20 micrograms · intranasal · two periods of 3 weeksAs given in this study (human).
Measurements
Dry nights
4.6 nights/week
second desmopressin period
Dry nights
2.4 nights/week
second placebo period
Source sentences
Summary
The number of dry nights, measured as calculated averages per week, increased significantly (p less than 0.01) from 0.6 dry nights during pre-treatment to 4.3 and 4.6 dry nights per week during the 2 desmopressin treatment periods, respectively.
3 context sentences(design, population, supporting numbers)
Summary · context
The placebo responses were 2.1 and 2.4 dry nights per week, respectively.
Summary · context
The effect of intranasal desmopressin on primary nocturnal enuresis was investigated in a study divided into 2 parts in which the first part was a randomized, double-blind, placebo-controlled cross-over study of 52 Finnish school children 5 to 13 years old.
Summary · context
The patients were randomized to 4 periods of 3 weeks each: 2 periods on placebo and 2 periods on 20 micrograms. desmopressin spray.
Report a problemFND-0200570804
03HumanNon-randomized trialEfficacy outcome
In children with nocturnal enuresis, desmopressin increased dry nights from 0.6 to 4.3 per week during the first treatment period.
In plain wordsIn children with bedwetting, desmopressin increased dry nights from 0.6 to 4.3 per week during the first treatment period.
Peptide
Desmopressin
Outcome
IncreaseDry nights during first desmopressin period
Study
n = 52
Comparator
Pretreatment
Outcome group
Urinary Continence · Kidney and urinary
Studied dose
20 micrograms · intranasal · 3-week treatment periodAs given in this study (human).
Measurements
Dry nights
0.6 nights/week
pretreatment
Dry nights
4.3 nights/week
first desmopressin period
p
< 0.01
versus pretreatment
Source sentences
Summary
The number of dry nights, measured as calculated averages per week, increased significantly (p less than 0.01) from 0.6 dry nights during pre-treatment to 4.3 and 4.6 dry nights per week during the 2 desmopressin treatment periods, respectively.
2 context sentences(design, population, supporting numbers)
Summary · context
The effect of intranasal desmopressin on primary nocturnal enuresis was investigated in a study divided into 2 parts in which the first part was a randomized, double-blind, placebo-controlled cross-over study of 52 Finnish school children 5 to 13 years old.
Summary · context
The patients were randomized to 4 periods of 3 weeks each: 2 periods on placebo and 2 periods on 20 micrograms. desmopressin spray.
Report a problemFND-0200570801
04HumanNon-randomized trialEfficacy outcome
In children with nocturnal enuresis, desmopressin increased dry nights from 0.6 to 4.6 per week during the second treatment period.
In plain wordsIn children with bedwetting, desmopressin increased dry nights from 0.6 to 4.6 per week during the second treatment period.
Peptide
Desmopressin
Outcome
IncreaseDry nights during second desmopressin period
Study
n = 52
Comparator
Pretreatment
Outcome group
Urinary Continence · Kidney and urinary
Studied dose
20 micrograms · intranasal · two periods of 3 weeksAs given in this study (human).
Measurements
Dry nights
0.6 nights/week
pretreatment
Dry nights
4.6 nights/week
second desmopressin period
p
< 0.01
versus pretreatment
Source sentences
Summary
The number of dry nights, measured as calculated averages per week, increased significantly (p less than 0.01) from 0.6 dry nights during pre-treatment to 4.3 and 4.6 dry nights per week during the 2 desmopressin treatment periods, respectively.
2 context sentences(design, population, supporting numbers)
Summary · context
The effect of intranasal desmopressin on primary nocturnal enuresis was investigated in a study divided into 2 parts in which the first part was a randomized, double-blind, placebo-controlled cross-over study of 52 Finnish school children 5 to 13 years old.
Summary · context
The patients were randomized to 4 periods of 3 weeks each: 2 periods on placebo and 2 periods on 20 micrograms. desmopressin spray.
Report a problemFND-0200570802
05HumanNon-randomized trialEfficacy outcome
In children with nocturnal enuresis, 47 patients relapsed after the crossover treatment period that included desmopressin.
In plain wordsIn children with bedwetting, 47 patients relapsed after the crossover treatment period that included desmopressin.
Peptide
Desmopressin
Outcome
Not applicableRelapse after crossover treatment
Study
n = 52
Outcome group
Urinary Continence · Kidney and urinary
Studied dose
20 micrograms · intranasal · two periods of 3 weeksAs given in this study (human).
Measurements
Relapsed
47 patients
post-treatment period in part 1
Source sentences
Summary
All 47 patients who relapsed during the post-treatment period in part 1 were included.
2 context sentences(design, population, supporting numbers)
Summary · context
The effect of intranasal desmopressin on primary nocturnal enuresis was investigated in a study divided into 2 parts in which the first part was a randomized, double-blind, placebo-controlled cross-over study of 52 Finnish school children 5 to 13 years old.
Summary · context
The patients were randomized to 4 periods of 3 weeks each: 2 periods on placebo and 2 periods on 20 micrograms. desmopressin spray.
Report a problemFND-0200570805
06HumanNon-randomized trialEfficacy outcome
In children with relapsed nocturnal enuresis, 53% responded fully during open desmopressin treatment.
In plain wordsIn children with relapsed bedwetting, 53% responded fully during open desmopressin treatment.
Peptide
Desmopressin
Outcome
Not applicableFull response during open treatment
Study
n = 47
Outcome group
Urinary Continence · Kidney and urinary
Studied dose
20, 30 and 40 micrograms · intranasal · 3 monthsAs given in this study (human).
Measurements
Full response
53%
open treatment
Source sentences
Summary
During this period 53% of the patients responded fully, 19% were intermediate responders and 28% did not respond.
1 context sentence(design, population, supporting numbers)
Summary · context
The second part of the study was an open dose-finding and drug safety study of a further 3 months in duration. The aim was to evaluate the efficacy and tolerance of 20, 30 and 40 micrograms. doses. All 47 patients who relapsed during the post-treatment period in part 1 were included.
Report a problemFND-0200570806
07HumanNon-randomized trialEfficacy outcome
In children with relapsed nocturnal enuresis, 19% were intermediate responders during open desmopressin treatment.
In plain wordsIn children with relapsed bedwetting, 19% were intermediate responders during open desmopressin treatment.
Peptide
Desmopressin
Outcome
Not applicableIntermediate response during open treatment
Study
n = 47
Outcome group
Urinary Continence · Kidney and urinary
Studied dose
20, 30 and 40 micrograms · intranasal · 3 monthsAs given in this study (human).
Measurements
Intermediate response
19%
open treatment
Source sentences
Summary
During this period 53% of the patients responded fully, 19% were intermediate responders and 28% did not respond.
1 context sentence(design, population, supporting numbers)
Summary · context
The second part of the study was an open dose-finding and drug safety study of a further 3 months in duration. The aim was to evaluate the efficacy and tolerance of 20, 30 and 40 micrograms. doses. All 47 patients who relapsed during the post-treatment period in part 1 were included.
Report a problemFND-0200570807
08HumanNon-randomized trialEfficacy outcome
In children with relapsed nocturnal enuresis, 28% did not respond during open desmopressin treatment.
In plain wordsIn children with relapsed bedwetting, 28% did not respond during open desmopressin treatment.
Peptide
Desmopressin
Outcome
Not applicableNonresponse during open treatment
Study
n = 47
Outcome group
Urinary Continence · Kidney and urinary
Studied dose
20, 30 and 40 micrograms · intranasal · 3 monthsAs given in this study (human).
Measurements
Nonresponse
28%
open treatment
Source sentences
Summary
During this period 53% of the patients responded fully, 19% were intermediate responders and 28% did not respond.
1 context sentence(design, population, supporting numbers)
Summary · context
The second part of the study was an open dose-finding and drug safety study of a further 3 months in duration. The aim was to evaluate the efficacy and tolerance of 20, 30 and 40 micrograms. doses. All 47 patients who relapsed during the post-treatment period in part 1 were included.
Report a problemFND-0200570808
09HumanNon-randomized trialEfficacy outcome
In children with relapsed nocturnal enuresis, continued desmopressin treatment had no effect on body weight.
In plain wordsIn children with relapsed bedwetting, continued desmopressin treatment had no effect on body weight.
Peptide
Desmopressin
Outcome
No significant changeBody weight during open treatment
Study
n = 47
Outcome group
Body weight · Metabolic and weight
Studied dose
20 to 40 micrograms · intranasal · 3 monthsAs given in this study (human).
Source sentences
Summary
During continued treatment for 3 months at doses between 20 and 40 micrograms. desmopressin was well tolerated, had no effect on body weight or blood pressure and did not cause any adverse reactions.
1 context sentence(design, population, supporting numbers)
Summary · context
The second part of the study was an open dose-finding and drug safety study of a further 3 months in duration. The aim was to evaluate the efficacy and tolerance of 20, 30 and 40 micrograms. doses. All 47 patients who relapsed during the post-treatment period in part 1 were included.
Report a problemFND-0200570809
10HumanNon-randomized trialEfficacy outcome
In children with relapsed nocturnal enuresis, continued desmopressin treatment had no effect on blood pressure.
In plain wordsIn children with relapsed bedwetting, continued desmopressin treatment had no effect on blood pressure.
Peptide
Desmopressin
Outcome
No significant changeBlood pressure during open treatment
Study
n = 47
Outcome group
Blood pressure · Cardiovascular
Studied dose
20 to 40 micrograms · intranasal · 3 monthsAs given in this study (human).
Source sentences
Summary
During continued treatment for 3 months at doses between 20 and 40 micrograms. desmopressin was well tolerated, had no effect on body weight or blood pressure and did not cause any adverse reactions.
1 context sentence(design, population, supporting numbers)
Summary · context
The second part of the study was an open dose-finding and drug safety study of a further 3 months in duration. The aim was to evaluate the efficacy and tolerance of 20, 30 and 40 micrograms. doses. All 47 patients who relapsed during the post-treatment period in part 1 were included.
Report a problemFND-0200570810
11HumanNon-randomized trialSafety outcome
In children with relapsed nocturnal enuresis, continued desmopressin treatment was well tolerated and caused no adverse reactions.
In plain wordsIn children with relapsed bedwetting, continued desmopressin treatment was well tolerated and caused no adverse reactions.
Peptide
Desmopressin
Outcome
Not applicableAdverse reactions during open treatment
Study
n = 47
Outcome group
Adverse events · Whole body
Studied dose
20 to 40 micrograms · intranasal · 3 monthsAs given in this study (human).
Source sentences
Summary
During continued treatment for 3 months at doses between 20 and 40 micrograms. desmopressin was well tolerated, had no effect on body weight or blood pressure and did not cause any adverse reactions.
1 context sentence(design, population, supporting numbers)
Summary · context
The second part of the study was an open dose-finding and drug safety study of a further 3 months in duration. The aim was to evaluate the efficacy and tolerance of 20, 30 and 40 micrograms. doses. All 47 patients who relapsed during the post-treatment period in part 1 were included.
Report a problemFND-0200570811

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
28 Oct 2026, 02:03 UTC
Study results updated
Version 1
27 Oct 2026, 16:35 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.